| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Agonist, Rosiglitazone, Ameliorates Ventricular Dysfunction in Experimental Chronic Mitral Regurgitation
1 Medicine, Veterans Affairs Medical Center, Houston, Texas, USA
* To whom correspondence should be addressed. E-mail: BlaseAnthony.Carabello{at}med.va.gov.
Objective: Previously we reported that the beneficial effects of 
-adrenergic blockade in chronic mitral regurgitation (MR) were in part due to induction of bradycardia, which obviously effects myocardial energy requirements. From this observation we hypothesized that part of the pathophysiology of MR may involve faulty energy substrate utilization, which in turn might lead to potentially harmful lipid accumulation observed in other models of heart failure. Methods: To explore this hypothesis, we measured triglyceride accumulation in the myocardium of dogs with chronic MR and then attempted to enhance myocardial metabolism by chronic administration of a PPAR 
agonist, rosiglitazone. Cardiac tissues were obtained from 3 groups of dogs: controls, dogs with MR for 3 months without treatment, and dogs with 6 months of MR treated with rosiglitazone 8mg/day for the last 3 months of observation. Hemodynamics and contractile function (end-systolic stress-strain relationship; K-index) were assessed at baseline, 3 months of MR, and 6 months of MR (3 months of the treatment). Results: Lipid accumulation in MR (Oil-Red-O staining score and thin layer chromatography) was marked and showed an inverse correlation with the LV contractility. LV contractility was significantly restored after PPAR therapy (K-index; 3.01 ±0.11* (therapy) vs. 2.12 ± 0.34 (3 mo MR) vs. 4.01 ± 0.29 (baseline), ANOVA p = 0.038, *p<0.05 vs. 3 mo MR). At the same time, therapy resulted in a marked reduction of intramyocyte lipid. Conclusion: We conclude that (1) chronic MR leads to intramyocyte myocardial lipid accumulation and contractile dysfunction and (2) administration of the PPAR agonist, rosiglitazone ameliorates MR-induced LV dysfunction accompanied by a decline in lipid content.
This article has been cited by other articles:
|
|
 |
|
  S. W. Rabkin and P. Lodha Stearic acid-induced cardiac lipotoxicity is independent of cellular lipid and is mitigated by the fatty acids oleic and capric acid but not by the PPAR agonist troglitazone Exp Physiol, August 1, 2009; 94(8): 877 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Neilan, T.-T. Ton-Nu, Y. Kawase, R. Yoneyama, K. Hoshino, F. del Monte, R. J. Hajjar, M. H. Picard, R. A. Levine, and J. Hung Progressive nature of chronic mitral regurgitation and the role of tissue Doppler-derived indexes Am J Physiol Heart Circ Physiol, May 1, 2008; 294(5): H2106 - H2111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. LeBrasseur, T.-A. S. Duhaney, D. S. De Silva, L. Cui, P. C. Ip, L. Joseph, and F. Sam Effects of Fenofibrate on Cardiac Remodeling in Aldosterone-Induced Hypertension Hypertension, September 1, 2007; 50(3): 489 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Crossno Jr., C. V. Garat, J. E. B. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, and D. J. Klemm Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling Am J Physiol Lung Cell Mol Physiol, April 1, 2007; 292(4): L885 - L897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rocic, B. Rezk, and P. A. Lucchesi PPAR-{gamma} agonists decrease hyperhomcysteinemia and cardiac dysfunction: new hope for ailing diabetic hearts? Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H26 - H28. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
